By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cardiovascular genomics test firm CardioDx has raised more than $40 million in a Series E financing round.

David Levison, CEO of the Palo Alto, Calif.-based company confirmed to GenomeWeb Daily News that the round raised more than $40 million, but he declined to provide a more exact figure. However, a document filed with the US Securities and Exchange Commission last week claimed the company has brought in $57.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.